Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Toxicol In Vitro ; 29(7): 1941-51, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26255146

RESUMEN

Cannabinoid receptor (CBs) agonists affect the growth of tumor cells via activation of deadly cascades. The spectrum of action of these agents and the precise role of the endocannabinoid system (ECS) on oncogenic processes remain elusive. Herein we compared the effects of synthetic (CP 55-940 and WIN 55,212-2) and endogenous (anandamide or AEA) CBs agonists (10-20 µM) on morphological changes, cell viability, and induction of apoptosis in primary astrocytes and in two glioblastoma cell lines (C6 and U373 cells) in order to characterize their possible differential actions on brain tumor cells. None of the CBs agonist tested induced changes in cell viability or morphology in primary astrocytes. In contrast, CP 55-940 significantly decreased cell viability in C6 and U373 cells at 5 days of treatment, whereas AEA and WIN 55,212-2 moderately decreased cell viability in both cell lines. Treatment of U373 and C6 for 3 and 5 days with AEA or WIN 55,212-2 produced discrete morphological changes in cell bodies, whereas the exposure to CP 55-940 induced soma degradation. CP 55-940 also induced apoptosis in both C6 and U373 cell lines. Our results support a more effective action of CP 55-940 to produce cell death of both cell lines through apoptotic mechanisms. Comparative aspects between cannabinoids with different profiles are necessary for the design of potential treatments against glial tumors.


Asunto(s)
Agonistas de Receptores de Cannabinoides/farmacología , Cannabinoides/farmacología , Animales , Apoptosis/efectos de los fármacos , Ácidos Araquidónicos/farmacología , Astrocitos/citología , Astrocitos/efectos de los fármacos , Benzoxazinas/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ciclohexanoles/farmacología , ADN , Endocannabinoides/farmacología , Humanos , Morfolinas/farmacología , Naftalenos/farmacología , Alcamidas Poliinsaturadas/farmacología , Ratas , Ratas Wistar
2.
Biochem Soc Trans ; 34(Pt 1): 17-21, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16246170

RESUMEN

The mRNA coding for FGF-2 (fibroblast growth factor 2), a major angiogenic factor, is translated by an IRES (internal ribosome entry site)-dependent mechanism. We have studied the role of the IRES in the regulation of FGF-2 expression in vivo, under pathophysiological conditions, by creating transgenic mice lines expressing bioluminescent bicistronic transgenes. Analysis of FGF-2 IRES activity indicates strong tissue specificity in adult brain and testis, suggesting a role of the IRES in the activation of FGF-2 expression in testis maturation and brain function. We have explored translational control of FGF-2 mRNA under diabetic hyperglycaemic conditions, as FGF-2 is implied in diabetes-related vascular complications. FGF-2 IRES is specifically activated in the aorta wall in streptozotocin-induced diabetic mice, in correlation with increased expression of endogenous FGF-2. Thus, under hyperglycaemic conditions, where cap-dependent translation is blocked, IRES activation participates in FGF-2 overexpression, which is one of the keys of diabetes-linked atherosclerosis aggravation. IRES activation under such pathophysiological conditions may involve ITAFs (IRES trans-acting factors), such as p53 or hnRNP AI (heterogeneous nuclear ribonucleoprotein AI), recently identified as inhibitory or activatory ITAFs respectively for FGF-2 IRES.


Asunto(s)
Factor 2 de Crecimiento de Fibroblastos/genética , Regulación de la Expresión Génica , Iniciación de la Cadena Peptídica Traduccional , Biosíntesis de Proteínas , Animales , Vasos Sanguíneos/metabolismo , Vasos Sanguíneos/patología , Codón Iniciador , Diabetes Mellitus/genética , Diabetes Mellitus/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Ratones , Ratones Transgénicos , Ribosomas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...